UnclassifiedAnnounced September 4, 2026
Business Pill, Branch Manager for Men — dietary supplements marketed for male sexual enhancement
Products contain undeclared yohimbine
Read FDA’s announcement (opens in a new tab)Recalls affecting Nevada
Data last updated: September 6, 2026 at 11:49 PM UTC
16,426 recalls foundJust announced
Straight from FDA press releases — not yet formally classified or risk-gradedUnclassifiedBacteria/virusAnnounced September 4, 2026
Foods Alive — Moringa Leaf Powder
Potential to be contaminated with Salmonella
Read FDA’s announcement (opens in a new tab)UnclassifiedAnnounced September 3, 2026
B. Braun — 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container
Presence of particulate matter identified as iron oxide
Read FDA’s announcement (opens in a new tab)UnclassifiedBacteria/virusAnnounced September 3, 2026
Great Value — Organic Triple Berry Blend
Possible E. Coli Contamination
Read FDA’s announcement (opens in a new tab)UnclassifiedAnnounced September 3, 2026
American Regent, Inc. — Epinephrine Injection, USP 30 mg/ 30 mL (1 mg/mL) multi dose vial
Presence of particulate matter and lack of sterility assurance
Read FDA’s announcement (opens in a new tab)UnclassifiedAnnounced August 31, 2026
Lipofit — Lipofit Extreme 2.0 Fat Burner Dietary Supplement
Undeclared Fluoxetine and 2,4-Dinitrophenol (DNP)
Read FDA’s announcement (opens in a new tab)UnclassifiedAnnounced August 31, 2026
Kofinas — Garlic Mediterranean Infused Extra Virgin Olive Oil 500 ml, 250 ml, and 100 ml
Contains garlic essential oil not approved for culinary use
Read FDA’s announcement (opens in a new tab)UnclassifiedAllergenAnnounced August 31, 2026
Little Temptations — Chocolatey Eyeballs, 7 oz., 10 oz., 10.5 oz., 11 oz., and 16 oz.
Undeclared milk
Read FDA’s announcement (opens in a new tab)UnclassifiedBacteria/virusAnnounced August 29, 2026
Everything Sprouts — Robust Radish Mix, 5oz Cups
Potential to be contaminated with Shiga toxin-producing Escherichia coli (STEC) or Salmonella.
Read FDA’s announcement (opens in a new tab)UnclassifiedBacteria/virusAnnounced August 29, 2026
Martina — Mangoes
Potential contamination with Salmonella
Read FDA’s announcement (opens in a new tab)Class IIILow risk
DrugRecalled June 13, 2023
Tranexamic Acid USP Tablets, 650 mg, 30 tablets (3X10) Unit Dose, Rx Only, Manufactured for: AvKARE Pulaski, TN 38478, NDC 50268-772-13
Failed Impurities/Degradation Specifications: not meeting quality requirements results obtained for conductivity.
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0875-2023
- Lot/product code:
- Lot: 44286 Exp. 02/2025
- Recalling firm:
- AVKARE LLC
Class IIILow risk
DrugRecalled June 23, 2023
PANCREAZE (pancrelipase) Delayed-Release Capsules, 100-count bottles, Rx only, Rx only, Manufactured by VIVUS LLC, Campbell, CA 95008, UPC: N3 62541-401-10 5, NDC 62541-401-10,
Failed Stability Specifications
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0896-2023
- Lot/product code:
- Lot #: 102101, Exp: 31 July 2024
- Recalling firm:
- Vivus, Inc.
Class IIILow risk
DrugRecalled July 27, 2023
Tobramycin Opthalmic Solution USP, 0.3%, 5mL bottle, Rx only, Manufactured for: Alembic Pharmaceuticals, Bedminster, NJ 07921, USA, NDC 62332-518-05
Failed Impurities/Degradation Specifications
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-1086-2023
- Lot/product code:
- Lot #: AMR103, Exp: 10/2023; Lot#: AMR201, Exp: 06/2024
- Recalling firm:
- ALEMBIC PHARMACEUTICALS, INC.
Class IIILow risk
DrugRecalled August 14, 2023
Trandolapril and Verapamil Hydrochloride Extended-Release Tablets 2 mg / 180 mg, 100-count Bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale -Bardez, Goa 403513, India, Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-295-01
Weaker than it should be: not meeting quality requirements for Assay Test at the 3-month time point.
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-1095-2023
- Lot/product code:
- Batch # 19224744
- Recalling firm:
- Glenmark Pharmaceuticals Inc., USA
Class IIILow risk
DrugRecalled August 14, 2023
Bendamustine HCl Injection, 100mg/4mL (25mg/mL), One 4 mL Multiple-Dose Vial, Rx only, Manufactured for Baxter Healthcare Corporation, Deerfield, IL 60015, NDC 10019-079-01.
Labeling: Missing Label; customer complaint received that labels were partially or completely peeled off injection vial.
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-1103-2023
- Lot/product code:
- Lots: 3A004A, 3A004B, Exp 12/31/2024; 3B005A, Exp 1/31/2025
- Recalling firm:
- Baxter Healthcare Corporation
Class IIILow risk
DrugRecalled August 16, 2023
Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108, NDC 72426-818-03
Failed dissolution specifications: below specification results at stability 12-month
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-1143-2023
- Lot/product code:
- Lot# 1904872, Exp 1/31/2025; 1950377, Exp 6/30/2025
- Recalling firm:
- Esperion
Class IIILow risk
DrugRecalled August 17, 2023
Sabril (vigabatrin) for Oral Solution, 500 mg, 50 Packets, Rx only, Manufactured by: Patheon, Cincinnati, OH 45237, NDC 67386-211-65
Cross contamination with other products
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-1142-2023
- Lot/product code:
- Lot#: 3207333A, 3207334A, Exp 03/2027; 3214707A, 3214709A, 3214710A, Exp 02/2028 .
- Recalling firm:
- Lundbeck LLC
Class IIILow risk
DrugRecalled October 17, 2023
Synthroid, Levothyroxine Sodium Tablets, USP 125mcg (0.125mg), 100-count bottle, Rx Only AbbVie Inc. North Chicago, IL 60064, U.S.A. NDC 0074-7068-11
Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose.
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0088-2024
- Lot/product code:
- Lot # 1187435 exp date: 02/2024
- Recalling firm:
- AbbVie Inc.
Class IIILow risk
DrugRecalled October 20, 2023
Oxaydo (oxycodone HCl, USP) tablets, 7.5 mg, 100 Tablets per bottle, Rx only, Distributed by: Zyla Life Sciences US Inc., Wayne, PA 19087. NDC: 69344-213-11
Weaker than it should be Drug: Lower potency than labeled.
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0094-2024
- Lot/product code:
- Lot 22W02, Exp 01/31/2025
- Recalling firm:
- Zyla Life Sciences US Inc.
Class IIILow risk
DrugRecalled November 10, 2023
Tropicamide 1% (10mg/mL), Cyclopentolate 1% (10mg/mL), Phenylephrine 2.5% (25mg/mL), Ketorolac 0.5% (5mg/mL), 5 mL bottles, For Topical Ophthalmic Use Only, Not for IV Use, This is a Compounded Drug, Hospital & Office Use Only, Fagron Sterile Services, 8710 E 34th St N Wichita, KS 67226. NDC 71266-8240-01
Labeling: Label Mix-Up: The label of a dropper bottle mistakenly states the container is a 0.5mL single-use syringe instead of a 5 mL dropper
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0125-2024
- Lot/product code:
- Lot #: C274-000033372, Exp. Date 01-17-2024; C274-000033764, Exp. Date 02-06-2024
- Recalling firm:
- Fagron Compounding Services
Class IIILow risk
DrugRecalled November 20, 2023
Votrient (pazopanib) 200 mg tablets, 120-count bottle, Rx Only, Manufactured by: Siegried Barbera, S.L., Barbera del Valles, Spain, Distributed by: Novartis Pharmaceuticals Corp., East Hanover, N.J. 07936, NDC 0078-1077-66
Failed Dissolution Specifications
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0149-2024
- Lot/product code:
- Lot# ME2713; Exp. 02/2025 Lot # MF8286, ML1860; Exp. 04/2025
- Recalling firm:
- Siegfried Barbera, SL
Class IIILow risk
DrugRecalled December 26, 2023
Benzonatate Capsules, USP, 100 mg, 100 Capsules (10 capsules x 10 unit dose cards), Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217. Carton NDC 68084-214-01; Individual Dose NDC 68084-214-11
Stronger than it should be drug: Assay results were slightly above specification at the time zero point.
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0257-2024
- Lot/product code:
- Lot # 1014208, Exp Mar/31/2025
- Recalling firm:
- Amerisource Health Services LLC
Class IIILow risk
DrugRecalled January 18, 2024
Glimepiride Tablets, USP 1mg, 100-count bottles, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Srikakulam-532 409 INDIA, NDC: 55111-320-01
Misprint on tablet
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0312-2024
- Lot/product code:
- Lot: T2303622; Exp. 06/2026 Lot: T2303626; Exp. 06/2026 Lot: T2303627; Exp. 06/2026 Lot: T2303628; Exp. 06/2026 Lot: T2303629; Exp. 06/2026
- Recalling firm:
- Dr. Reddy's Laboratories, Inc.
Class IIILow risk
DrugRecalled January 18, 2024
Glimepiride Tablets, USP 1mg, 500-count bottles, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Srikakulam-532 409 INDIA, NDC: 55111-320-05
Misprint on tablet
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0313-2024
- Lot/product code:
- Lot: T2303609; Exp. 06/2026 Lot: T2303610; Exp. 06/2026
- Recalling firm:
- Dr. Reddy's Laboratories, Inc.
Class IIILow risk
DrugRecalled January 25, 2024
Nortrel (norethindrone and ethinyl estradiol tablets USP) 0.5/35, packaged in cartons, each carton contains 3 blister cards, each card contains 28 tablets, Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0555-9008-67
Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0321-2024
- Lot/product code:
- Lot #: 100042978, Exp 7/31/2024
- Recalling firm:
- Teva Pharmaceuticals USA, Inc
Class IIILow risk
DrugRecalled January 25, 2024
Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen), packaged in cartons, each carton contains 6 blister cards, each card contains 28 tablets, Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0555-9012-58
Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0322-2024
- Lot/product code:
- Lot #: 100040731, Exp 7/31/2024
- Recalling firm:
- Teva Pharmaceuticals USA, Inc
Class IIILow risk
DrugRecalled February 1, 2024
HydrALAZINE Hydrochloride Tablets, USP, 10 mg, 100-count (10 x 10) per unit dose carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217. NDC Carton: 68084-447-01; NDC Unit Dose: 68084-447-11
Failed Impurities/Degradation Specifications: not meeting quality requirements (OOS) result in the repackaged product for Related Compounds (Impurities) at the 6-month time point.
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0320-2024
- Lot/product code:
- Lot #: 1012275, Exp 02/28/2025
- Recalling firm:
- Amerisource Health Services LLC
Class IIILow risk
DrugRecalled February 20, 2024
Clindamycin Phosphate, Topical Solution USP, 1%, 60 mL, Rx Only, Manufactured for and Distributed by: Marlex Pharmaceuticals, Inc., New Castle, DE 19720, NDC 10135-0691-61
Defective Container: not meeting quality requirements for weight due to a slow leakage at the 12-month stability timepoint.
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0364-2024
- Lot/product code:
- Lot #: 119466, 119467 Exp 04/2025; 120351 Exp 08/2025; 121712 Exp 11/2025
- Recalling firm:
- Contract Pharmaceuticals Limited Canada
Class IIILow risk
DrugRecalled February 20, 2024
Clindamycin Phosphate Topical Solution USP, 1%, 60 mL bottle, Manufactured for: Glasshouse Pharmaceuticals Limited Canada, Mississauga, Ontario, Canada, L5N 6R8, NDC 71428-0003-60
Defective Container: not meeting quality requirements for weight due to a slow leakage at the 12-month stability timepoint.
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0365-2024
- Lot/product code:
- Lot #: 119874; Exp 06/30/2025
- Recalling firm:
- Contract Pharmaceuticals Limited Canada
Class IIILow risk
DrugRecalled March 27, 2024
NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03
Failed dissolution specifications: not meeting quality requirements bempedoic acid dissolution at the 0-month timepoint.
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0441-2024
- Lot/product code:
- Lot #, 1990305, Exp 08-31-2025
- Recalling firm:
- Esperion
Class IIILow risk
DrugRecalled April 9, 2024
Abilify (aripiprazole), 30 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-011-13
Cross Contamination with Other Products
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0469-2024
- Lot/product code:
- Lot # APS00423A, Exp 07/31/2025; APS00222A, Exp 11/30/2024
- Recalling firm:
- Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
Class IIILow risk
DrugRecalled April 9, 2024
Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13
Cross Contamination with Other Products
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0466-2024
- Lot/product code:
- Lot # AKS00623A, Exp 01/31/2026; AKS00322A, Exp 02/28/2025
- Recalling firm:
- Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
Class IIILow risk
DrugRecalled April 9, 2024
Abilify (aripiprazole), 10 mg tablets, packaged in a) 30 count bottles (NDC 59148-008-13) and b) 7 count blister packs (NDC 59148-008-95), RX only, Otsuka America Pharmaceutical, Inc.
Cross Contamination with Other Products
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0467-2024
- Lot/product code:
- Lot #: a) ALS00422A, Exp 04/30/2025; ALS00523A, Exp 11/30/2025; b) 1K77YUD1H1A, Exp 11/30/2024
- Recalling firm:
- Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
Class IIILow risk
DrugRecalled April 9, 2024
Abilify (aripiprazole), 15 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-009-13
Cross Contamination with Other Products
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0468-2024
- Lot/product code:
- Lot # AMS00223A, Exp 07/31/2025
- Recalling firm:
- Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
Class IIILow risk
DrugRecalled April 10, 2024
Epinephrine-Lidocaine HCl 0.25 mg/mL and 7.5 mg/mL Preservative-Free, 1 mL Single-Use vials, Rx only, Imprimis NJOF, LLC 1705 Route 46 West, Unit 6B, Ledgewood, NJ, 07852, NDC 71384-640-01
Not meeting quality requirements for assay
ALL 50 STATES
▸Full report
A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.
- Recall #:
- D-0478-2024
- Lot/product code:
- Lot #: 23JUL028, Exp. Date 8/1/2024; 23AUG053, Exp. Date 8/30/2024
- Recalling firm:
- Imprimis NJOF, LLC